poisar

Stocks · News reference

Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications

Vandana Singh

FDA warns of risks from unapproved compounded GLP-1 drugs including semaglutide and tirzepatide amid rising adverse event reports.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

HIMSLLYNVO
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Kaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (NYSE: HIMS) Who Suffered Losses to Contact the Firm Before November 2, 2026

    Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.

    HIMSHYLNINV
  2. Hagens Berman

    Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS

    Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.

    HIMSMETASNAP
  3. Na

    HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss

    Hims & Hers reported Q2 2026 revenue of $753.2M, up 38.2% YoY, driven by subscriber growth to 2.9M and higher spending per subscriber. The company raised full-year 2026 revenue guidance to $3.1B-$3.3B (32-41% growth). However, gross margins contracted sharply to 63.8% due to lower-margin weight loss products and international expansion, resulting in an $86.3M net loss and widening loss per share estimates.

    HIMSNVOLLY
  5. Nxera Pharma

    Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress

    Nxera Pharma announced it will receive an $8.6 million milestone payment from Centessa Pharmaceuticals (a subsidiary of Eli Lilly) following late-stage development progress on selective orexin receptor 2 (OX2R) agonist candidates. The payment will be recognized as revenue in Q3 2026. Nxera retains rights to future development, commercialization milestones, and royalties from the OX2R agonist programs.

    LLY
  6. Robert Izquierdo

    Healthcare ETF Comparison: Fidelity's FHLC vs. Invesco's Biotech-Focused IBBQ

    Fidelity's FHLC and Invesco's IBBQ offer different healthcare investment strategies. FHLC provides broad exposure to 365 healthcare holdings with a lower 0.08% expense ratio and 1.2% dividend yield, while IBBQ focuses on biotech with higher volatility, delivering 56.4% 1-year returns but experiencing a 37.9% maximum drawdown. The choice depends on investor risk tolerance and diversification preferences.

    FHLCIBBQLLYJNJABBV